Inactive Instrument

Pharmacyclics, Inc. Stock

Stocks

End-of-day quote Nasdaq Other stock markets
- ^USD	-

15-05-06	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
15-04-29	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

15-05-06	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
15-04-29	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
15-04-21	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
15-04-21	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
15-04-08	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
15-03-05	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
15-03-05	Wall Street closes up slightly ahead of jobs report	RE
15-03-05	AbbVie : CEO says new form of Humira could thwart generics	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
15-03-05	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
14-06-02	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

16-01-07	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
16-01-07	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
16-01-07	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
16-01-07	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
16-01-07	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

15-03-05	Wall Street se reprend un peu dans un climat d'attente
15-03-05	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
15-03-05	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
15-03-05	Début d'année en fanfare pour les fusions dans la pharmacie
15-03-05	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	2013-01-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+1.08%	+7.56%	+3.61%	+9.84%	49.92B
REVOLUTION MEDICINES, INC.	+0.40%	-1.37%	+401.69%	+625.15%	40.23B
IQVIA HOLDINGS INC.	-0.52%	+6.57%	+25.41%	-5.37%	34.55B
BEONE MEDICINES AG	+3.97%	+6.71%	+26.06%	+63.36%	33.09B
CELLTRION, INC.	-4.19%	-1.84%	+3.76%	+32.17%	27.51B
ASCENDIS PHARMA A/S	-2.40%	+1.60%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+1.34%	+5.68%	+75.77%	+141.51%	15.92B
EUROFINS SCIENTIFIC SE	-0.95%	+0.76%	+12.92%	+21.59%	13.86B
IONIS PHARMACEUTICALS, INC.	+1.69%	+3.09%	+93.44%	+99.19%	13.52B
Average	+0.05%	+4.25%	+80.33%	+123.43%	27.3B
Weighted average by Cap.	+0.24%	+4.49%	+91.13%	+141.43%

Employees

Sector